Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

g. OGX-427 is designed to reduce levels of Hsp27, a heat shock protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy, and radiation therapy. Results demonstrated that OGX-427 was safe and well tolerated as monotherapy, as well as in combination with docetaxel. In addition, when OGX-427 was used as a single agent there were declines in circulating tumor cells in patients at all doses and in all diseases evaluated, as well as evidence of reduction in tumor markers in prostate and ovarian cancer. - Partnering discussions and assessment of other opportunities to expand the development plan into additional randomized Phase 2 trials will continue. - A Phase 1 trial in bladder cancer is currently underway. - A randomized Phase 2 trial in CRPC is expected to initiate later this year.

Financial Results

Under our Collaboration Agreement with Teva relating to our contribution to the custirsen Phase 3 development plan, we earned Collaboration Revenues of $1.7 million and $6.4 million, respectively, for the three and six months ended June 30, 2010, compared to no revenues in the corresponding periods of 2009. Of the revenues in the second quarter, $362 thousand is reimbursable from Teva on a cash basis and is included on the Company's balance sheet as amounts receivable at June 30, 2010. As of June 30, 2010, $24.1 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our del
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... Netherlands, May 14 Nucletron, a,knowledge-based leader ... release,of Oncentra(R) Brachy, a comprehensive film- and ... planning for brachytherapy.,Oncentra Brachy, the world,s first ... Windows-based planning system that features,state-of-the-art optimization algorithms ...
... 14 Experts from PAREXEL Consulting will present insights ... to be held May 18-21, 2009 at the Georgia ... a business unit of PAREXEL International (Nasdaq: ... and medical device industries. PAREXEL Consulting experts will be ...
... Pharmaxis (ASX: PXS;,Nasdaq: PXSL ) today announced ... Drug Administration (FDA) that the New Drug Application (NDA),for ... for,standard review. The FDA will advise the result ... Pharmaxis is seeking approval for Aridol for ...
Cached Biology Technology:Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4U.S. FDA Accepts Aridol(TM) New Drug Application for Review 2
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... People diagnosed with Huntington,s disease, most in their ... mental, physical, and behavioral decline within two decades. ... of the genetic disease, have been the primary ... But according to new research from Prof. Gerardo ... University,s Department of Cell Research and Immunology, in ...
(Date:4/23/2014)... Valley, NY. (Apr. 23 2014) A ... neural stem cells (hNSCs) into the brains of ... after 22 and 24 months found that the ... and did not cause tumors. , The study ... Cell Transplantation but is currently freely ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Chironex species are among the most venomous animals in ... venom, though, which kills by rapidly punching holes in human ... according to research published December 12 in the open access ... University of Hawaii and colleagues. The researchers ...
... be some in that cookie? Now you can find out ... A team of researchers from the UCLA Henry Samueli School ... called the iTube, which attaches to a common cell phone ... the cell phone,s built-in camera, along with an accompanying smart-phone ...
... the Great Lakes, including phosphorus-rich Lake Erie, is an age-old ... of scientists, including Mercyhurst University biologist Steven Mauro, Ph.D. ... avian botulism are linked to Cladophora and scientific ... renewed attention in the nuisance algae. For Mauro, whose ...
Cached Biology News:Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 2Got food allergies? Thanks to UCLA, you can test your meal on the spot using a cell phone 3Grant furthers Mercyhurst research for human pathogens in Great Lakes 2
...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... siRNA Custom Synthesis Service provides ... RNA to knockdown any gene. ... RNA base pairs with terminal ... or other lengths of your ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: